Clinical Trial

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 13, 2023 (before its estimated July 27, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05998928
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Guangzhou Bio-gene Technology Co., Ltd
Conditions Multiple Myeloma
Enrollment 10 participants
Start Date 2023-07-27
Primary Completion 2025-07-27 (estimated)
Study Completion 2026-07-27 (estimated)
Updated on ClinicalTrials.gov 2023-11-13